Concise review: The role of clinical trials in deciphering mechanisms of action of cardiac cell-based therapy

Viky Y. Suncion, Ivonne H Schulman, Joshua Hare

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Although the initial promise of cardiac cell-based therapy was based on the concept that stem cells engraft into diseased tissue and differentiate into beating cardiomyocytes, it is now clear that successful cell-based tissue repair involves a more complex orchestration of cellular and molecular events. Many lessons about successful tissue repair can be gleaned from the results of early-stage clinical trials. This body of work shows that cell-based therapy (with various cell sources and delivery methods) effectively prevents and reverses the remodeling process, the sine qua non of the myocardial injury reaction and anatomic substrate for subsequent clinical events. The potentially favorable remodeling responses to cell therapy have prompted a search for mechanisms of action beyond cell repopulation and guided future clinical trial design by providing more clear focus on pathophysiological endpoints signifying favorable responses to cell-based therapy. Perhaps the most important mechanistic insight is that endogenous stem/precursor cells have the potential to participate in tissue healing. With regard to the phenotype of cellular response, it is clear that parameters of remodeling, such as infarct size and ventricular dimensions, should be directly measured, thereby necessitating the use of sophisticated imaging modalities, such as cardiac magnetic resonance imaging or multidetector computed tomography. These new insights offer an optimistic outlook on the state of cell-based therapeutics for cardiac disease and suggest that pivotal clinical trials are warranted. Here, we review lessons learned from clinical trials and evaluate the choice and assessment of endpoints to best predict efficacy of cell therapy.

Original languageEnglish
Pages (from-to)29-35
Number of pages7
JournalStem cells translational medicine
Volume1
Issue number1
DOIs
StatePublished - Dec 1 2012

Fingerprint

Cell- and Tissue-Based Therapy
Clinical Trials
Stem Cells
Multidetector Computed Tomography
Cardiac Myocytes
Heart Diseases
Magnetic Resonance Imaging
Phenotype
Wounds and Injuries
Therapeutics

Keywords

  • Cell transplantation
  • Heart failure
  • Magnetic resonance imaging
  • Mesenchymal stem cells
  • Myocardial infarction
  • Ventricular remodeling

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology
  • Medicine(all)

Cite this

@article{8d851462d2984ef4858a416b26449e8e,
title = "Concise review: The role of clinical trials in deciphering mechanisms of action of cardiac cell-based therapy",
abstract = "Although the initial promise of cardiac cell-based therapy was based on the concept that stem cells engraft into diseased tissue and differentiate into beating cardiomyocytes, it is now clear that successful cell-based tissue repair involves a more complex orchestration of cellular and molecular events. Many lessons about successful tissue repair can be gleaned from the results of early-stage clinical trials. This body of work shows that cell-based therapy (with various cell sources and delivery methods) effectively prevents and reverses the remodeling process, the sine qua non of the myocardial injury reaction and anatomic substrate for subsequent clinical events. The potentially favorable remodeling responses to cell therapy have prompted a search for mechanisms of action beyond cell repopulation and guided future clinical trial design by providing more clear focus on pathophysiological endpoints signifying favorable responses to cell-based therapy. Perhaps the most important mechanistic insight is that endogenous stem/precursor cells have the potential to participate in tissue healing. With regard to the phenotype of cellular response, it is clear that parameters of remodeling, such as infarct size and ventricular dimensions, should be directly measured, thereby necessitating the use of sophisticated imaging modalities, such as cardiac magnetic resonance imaging or multidetector computed tomography. These new insights offer an optimistic outlook on the state of cell-based therapeutics for cardiac disease and suggest that pivotal clinical trials are warranted. Here, we review lessons learned from clinical trials and evaluate the choice and assessment of endpoints to best predict efficacy of cell therapy.",
keywords = "Cell transplantation, Heart failure, Magnetic resonance imaging, Mesenchymal stem cells, Myocardial infarction, Ventricular remodeling",
author = "Suncion, {Viky Y.} and Schulman, {Ivonne H} and Joshua Hare",
year = "2012",
month = "12",
day = "1",
doi = "10.5966/sctm.2011-0014",
language = "English",
volume = "1",
pages = "29--35",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "1",

}

TY - JOUR

T1 - Concise review

T2 - The role of clinical trials in deciphering mechanisms of action of cardiac cell-based therapy

AU - Suncion, Viky Y.

AU - Schulman, Ivonne H

AU - Hare, Joshua

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Although the initial promise of cardiac cell-based therapy was based on the concept that stem cells engraft into diseased tissue and differentiate into beating cardiomyocytes, it is now clear that successful cell-based tissue repair involves a more complex orchestration of cellular and molecular events. Many lessons about successful tissue repair can be gleaned from the results of early-stage clinical trials. This body of work shows that cell-based therapy (with various cell sources and delivery methods) effectively prevents and reverses the remodeling process, the sine qua non of the myocardial injury reaction and anatomic substrate for subsequent clinical events. The potentially favorable remodeling responses to cell therapy have prompted a search for mechanisms of action beyond cell repopulation and guided future clinical trial design by providing more clear focus on pathophysiological endpoints signifying favorable responses to cell-based therapy. Perhaps the most important mechanistic insight is that endogenous stem/precursor cells have the potential to participate in tissue healing. With regard to the phenotype of cellular response, it is clear that parameters of remodeling, such as infarct size and ventricular dimensions, should be directly measured, thereby necessitating the use of sophisticated imaging modalities, such as cardiac magnetic resonance imaging or multidetector computed tomography. These new insights offer an optimistic outlook on the state of cell-based therapeutics for cardiac disease and suggest that pivotal clinical trials are warranted. Here, we review lessons learned from clinical trials and evaluate the choice and assessment of endpoints to best predict efficacy of cell therapy.

AB - Although the initial promise of cardiac cell-based therapy was based on the concept that stem cells engraft into diseased tissue and differentiate into beating cardiomyocytes, it is now clear that successful cell-based tissue repair involves a more complex orchestration of cellular and molecular events. Many lessons about successful tissue repair can be gleaned from the results of early-stage clinical trials. This body of work shows that cell-based therapy (with various cell sources and delivery methods) effectively prevents and reverses the remodeling process, the sine qua non of the myocardial injury reaction and anatomic substrate for subsequent clinical events. The potentially favorable remodeling responses to cell therapy have prompted a search for mechanisms of action beyond cell repopulation and guided future clinical trial design by providing more clear focus on pathophysiological endpoints signifying favorable responses to cell-based therapy. Perhaps the most important mechanistic insight is that endogenous stem/precursor cells have the potential to participate in tissue healing. With regard to the phenotype of cellular response, it is clear that parameters of remodeling, such as infarct size and ventricular dimensions, should be directly measured, thereby necessitating the use of sophisticated imaging modalities, such as cardiac magnetic resonance imaging or multidetector computed tomography. These new insights offer an optimistic outlook on the state of cell-based therapeutics for cardiac disease and suggest that pivotal clinical trials are warranted. Here, we review lessons learned from clinical trials and evaluate the choice and assessment of endpoints to best predict efficacy of cell therapy.

KW - Cell transplantation

KW - Heart failure

KW - Magnetic resonance imaging

KW - Mesenchymal stem cells

KW - Myocardial infarction

KW - Ventricular remodeling

UR - http://www.scopus.com/inward/record.url?scp=84864251872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864251872&partnerID=8YFLogxK

U2 - 10.5966/sctm.2011-0014

DO - 10.5966/sctm.2011-0014

M3 - Article

C2 - 23197637

AN - SCOPUS:84864251872

VL - 1

SP - 29

EP - 35

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 1

ER -